Posted by Michael Wonder on 27 Apr 2023
UCB receives positive CHMP opinions for bimekizumab for the treatment of adults with psoriatic arthritis and axial spondyloarthritis in the European Union
27 April 2023 - Positive CHMP opinions are supported by data from four Phase 3 studies that evaluated bimekizumab in active psoriatic arthritis (BE COMPLETE and BE OPTIMAL) and active axial spondyloarthritis (BE MOBILE 1 and BE MOBILE 2).
UCB today announced that the CHMP of the EMA has issued positive opinions recommending granting marketing authorization for bimekizumab in the European Union for the treatment of adults with active axial spondyloarthritis and for adults with active psoriatic arthritis.
